港股異動 | 復鋭醫療科技(1696.HK)大漲超12%有望挑戰新高 發盈喜後獲投行唱好
格隆匯7月12日丨復鋭醫療科技(1696.HK)大幅拉昇漲超12%,報21.5港元有望再度挑戰新高價,總市值達95億港元。近日復鋭醫療科技發佈2021年中期業績預吿,其中營業收入同比增長超過73%,淨利潤同比增長超過190%。天風證券點評稱,公司收入增速大超預期,盈利能力顯著提升。預計2021年全年及未來年度盈利能力有望逐步恢復。此外,新技術及新產品的推出能夠為公司的業績增長帶來新的驅動力,以支撐公司在競爭激烈的醫美行業中保持競爭優勢,滿足更多的求美需求。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.